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Background
Systemic AL Amyloidosis causes multiorgan dysfunction
through interstitial expansion. We measured the extracel-
lular volume fraction (ECV) in the : heart, liver, spleen and
skeletal muscle in healthy volunteers and patients with
Systemic Amyloidosis to test the hypotheses that (1) tissue
ECV is greater in systemic AL Amyloidosis than in health
and (2) ECV tracks organ amyloid burden.
Methods
Healthy volunteers (n=70; 35 male; 35 female; median age
46 years) and patients with systemic AL Amyloidosis
(n=56; 36 male; 20 female; median age 62 years), with clin-
ical indications for CMR scanning, additionally underwent
multi-organ ECV measurement. Technical details were:
gadoteric acid, 0.1mmol/Kg plus infusion, multibreath-
hold T1 measurement and equilibrium imaging of heart,
liver spleen and biceps muscle at 1.5T (Siemens Avanto).
Amyloidosis patients also underwent serum amyloid P
component (SAP) scintigraphy to score liver and spleen
involvement by amyloid.
Results
ECV of the heart, liver, spleen and muscle was signifi-
cantly elevated in patients with amyloidosis (0.40, 0.33,
0.42 and 0.12 respectively) compared to healthy controls
(0.25, 0.30, 0.34 and 0.09 respectively) (P<0.001). ECV
measured in the liver and spleen tracked increasing
organ amyloid burden assessed by SAP scintigraphy
(P<0.001). In healthy volunteers, ECV varied between dif-
ferent organs, being highest in the spleen and lowest in
skeletal muscle.
Conclusions
The cardiac ECV technique measures cardiac amyloid
burden, but can be translated into also in other tissues
and organs in the body. Here its use is validated against
the gold standard of SAP scanning in the liver and
spleen. ECV measurement may represent a key techni-
que for measuring ECV increase in systemic diseases.
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Figure 1 comparing mean ECVs of heart, liver, spleen and biceps
muscle in normal volunteers VS patients with amyloidosis.
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Figure 2 showing ECV tracking amyloid burden when compared to SAP imaging score for liver (left) and spleen (right).
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